Interestingly, both products and substrates of the RA pathway, 5 μM atRA and 1 μM ROL, respectively, were shown to inhibit ALDH1+ CSC populations in cisplatin-resistant NSCLC cells [258]. The gene discussed is ALDH1A1; the disease is non-small cell lung carcinoma.